Q3 2024 Egetis Therapeutics AB (publ) Earnings Call TranscriptNov 08, 2024kr4.24Earnings- Egetis Therapeutics AB Egetis Investor Day TranscriptDec 19, 2023
- Egetis Therapeutics AB (publ) To Discuss Demonstrating Treatment effects on T3 levels in MCT8-deficiency marketing approval for Emcitate® in the US Call TranscriptJan 18, 2022
Q3 2024 Egetis Therapeutics AB (publ) Earnings Call Transcript
()-
Thank you operator, good morning and a warm welcome to GT Therapeutics Webcast for the quarter three reports and results.
For those I haven't had the privilege to meet before. My name is Nicklas Westerholm and I am the CEO of the company with me today. I also have our CFO Yilmaz Mahshid, Karl HÃ¥rd, our head of investor relations and business development and Henrik Krook, our head of commercial operations globally.
What we are planning to cover today are updates on several important milestones delivered during the quarter.
We will touch upon the progress for our marketing authorization application for MCT8 with the EMA.
The guidelines for diagnosis and management of MCT8 deficiency issued in July by the European Thyroid Association.
The new data published through an abstract concerning survival. The data was presented at the 46th annual meeting of the European Thyroid Association in September.
The retrack status, obviously important
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
